Searched over 200M research papers
10 papers analyzed
These studies suggest atenolol rapidly reduces heart rate with peak effects observed at 2-5 hours after administration.
20 papers analyzed
Atenolol is a cardioselective beta-blocker commonly used to manage cardiovascular conditions such as hypertension, angina pectoris, and arrhythmias. One of its primary therapeutic effects is the reduction of heart rate, which is crucial for patients with various cardiac conditions. Understanding the onset and duration of atenolol's heart rate-lowering effects is essential for optimizing its clinical use.
Atenolol is rapidly absorbed when administered orally, with significant reductions in heart rate observable within 30 minutes of ingestion. This quick onset makes atenolol effective for acute management of conditions requiring immediate heart rate control.
In acute settings, such as suspected acute myocardial infarction, intravenous administration of atenolol can lead to a significant reduction in heart rate within the first hour. In a study involving patients with acute myocardial infarction, heart rate decreased from 77 beats per minute to 65 beats per minute within the first hour after intravenous administration.
Atenolol's heart rate-lowering effects are sustained over a 24-hour period, particularly with higher doses. Studies have shown that atenolol maintains its efficacy in reducing heart rate throughout the day, with significant effects still observable 24 hours post-dosing . This makes atenolol suitable for once-daily dosing in chronic management.
When compared to other beta-blockers such as nadolol and metoprolol, atenolol demonstrates a substantial heart rate-lowering effect, although it may not be as prolonged as nadolol. For instance, nadolol maintains 80-100% of its heart rate-attenuating effect 24 hours after administration, whereas atenolol maintains 20-45% of its effect. However, atenolol still provides significant heart rate control over a 24-hour period, making it effective for daily use.
Atenolol is effective in reducing heart rate and blood pressure in patients with hypertension and angina pectoris. In a study comparing atenolol with metoprolol, atenolol was found to be more effective in controlling heart rate and blood pressure over a 22-hour period. Additionally, atenolol has been shown to improve exercise tolerance and reduce anginal attacks in patients with stable angina.
Atenolol also positively impacts heart rate variability (HRV), which is an indicator of autonomic regulation of the heart. Increased HRV is associated with better cardiovascular outcomes. Studies have shown that atenolol increases measures of vagal activity, contributing to its beneficial effects on HRV .
Atenolol is a highly effective beta-blocker for reducing heart rate, with rapid onset and sustained effects over 24 hours. Its efficacy in managing hypertension, angina, and arrhythmias, along with its positive impact on heart rate variability, makes it a valuable therapeutic option in cardiovascular medicine. Understanding the pharmacokinetics and pharmacodynamics of atenolol helps in optimizing its use for better patient outcomes.
Most relevant research papers on this topic